Researchers develop pathoblockers to combat bacterial pneumonia toxins

In most cases, antibiotics are a reliable form of protection against bacterial infections. They have saved billions of human lives since their introduction. This protection, however, is threatened by bacteria's resistance to classical antibiotics and by their aggressive pathogenicity. Currently, one in seven bacterial pneumonia patients in Germany dies while hospitalized - despite the use of antibiotics. This amounts to about 30,000 people per year. The cause of death in these cases is often toxins released by the bacteria, which attack and ultimately destroy the cells of the infected person. Antibiotics do not protect against these bacterial toxins. A study published in Nature Communications now raises hopes for new treatment options.

Researchers at Freie Universität Berlin and Charité - Universitätsmedizin Berlin have succeeded in developing molecules that provide protection against the most common pneumonia-inducing pathogens. They are calling these molecules "pathoblockers." The novel substances do not kill the bacteria, but instead switch off the toxins they produce. Normally, these toxins attack the cell membrane of human cells during an infection, piercing small holes into them, thereby killing the cells.

We have identified molecules that inactivate bacterial toxins even at low concentrations, rendering them harmless. By applying these compounds, we were able to show that it should be feasible to completely protect human lung cells."

Jörg Rademann, professor of pharmaceutical and medicinal chemistry at Freie Universität Berlin and director of the research project

In their paper, published recently in the prestigious Nature Communications journal, Rademann's group demonstrated that the new pathoblockers modify the bacterial toxins in such a way that they lose their aggressive toxicity. The researchers are continuing to investigate whether such novel pathoblockers might be applicable for clinical use in the future.